Compounded topical finasteride: FDA status, absorption, and product questions

No topical finasteride formulation—alone or combined with minoxidil—is FDA-approved in the United States. A state-licensed pharmacy or registered outsourcing facility may compound a topical product only when the applicable conditions of section 503A or 503B are met; compounding is not approval. FDA warns that topical finasteride can be systemically absorbed and can expose other people through skin contact or residue.¹³

That direct answer is narrower than “topical is unsafe” and more accurate than “topical has no systemic effects.” The product, concentration, vehicle, dose per actuation, treated area, application pattern, pharmacy, and household precautions all matter.

Four different offers can share one name

The word “prescription” shows that a prescriber is involved; it does not show FDA approved the finished product. Similarly, an NDC-style number, pharmacy registration, or lab result cannot substitute for approval.

Topical does not mean local-only

FDA’s alert states that absorption through skin into the bloodstream is expected and that reported adverse events are consistent with known oral-finasteride risks.¹ The amount of exposure may differ from an oral product, but “less” cannot be assumed for every formula or application pattern.

Ask the prescription to specify:

• finasteride concentration and every other active ingredient;
• vehicle and total volume;
• dose per spray, pump, drop, or measured amount;
• number of applications and treated area;
• total daily finasteride delivered when used as directed;
• drying, handwashing, storage, and missed-dose instructions; and
• what should prevent contact by another person.

A percentage alone is not a dose. A 0.1% solution applied in one volume can deliver a different amount than the same percentage used with another pump or surface area.

Transfer exposure needs a household plan

Residue can remain on hands, counters, pillowcases, hats, hair, or treated skin. FDA highlights potential transfer exposure, including concern for pregnant people because finasteride can affect male fetal development.¹

The pharmacy label should give product-specific contact, drying, washing, storage, spill, and disposal instructions. “Let dry” is incomplete if it does not define how long, what surfaces to avoid, and what to do after accidental contact.

This is not a reason to invent a universal isolation period. Vehicles and directions differ. It is a reason to require the prescriber and pharmacy to make the transfer plan explicit.

Adverse-event counts are a signal, not a rate

FDA said it had received 32 adverse-event reports associated with compounded topical finasteride from 2019 through 2024.¹ Those reports included sexual, psychiatric, cognitive, and other symptoms. A passive report can identify a safety signal, but it cannot show incidence, prove causation, or compare topical with oral risk because exposure totals, verification, duplicates, underlying conditions, and reporting behavior are incomplete.

The AEMS and MAUDE guide explains those limits. A clinic should not use “only 32” to prove rarity or “32 FDA cases” to prove a causal rate.

Combination formulas multiply the identity problem

Telehealth products may combine finasteride with minoxidil, tretinoin, corticosteroids, or other ingredients. Evidence for one component or one formula does not automatically support the combination, concentration, vehicle, or schedule being sold.

The oral-versus-topical minoxidil guide owns that separate ingredient decision. For a combination, require the rationale and risk information for every active ingredient, plus a plan for determining which ingredient caused irritation or another concern.

Verify the pharmacy and the prescriber separately

503A pharmacies and 503B outsourcing facilities are not interchangeable. A 503A pharmacy generally compounds based on patient-specific prescriptions under conditional exemptions; a 503B facility can compound certain office-stock products under a different set of conditions.³ Neither pathway is FDA approval.

Use the compounding-pharmacy guide to match the label to the actual dispensing pharmacy and any named maker. Preserve the prescription, package, lot, beyond-use date, shipping temperature, and complaint contact.

A defensible telehealth checkout

1. Identify the clinical question. Record the hair-loss diagnosis being considered and why finasteride is part of the plan.
2. Translate concentration into delivered dose. Capture active ingredients, percentage, pump or drop volume, frequency, and treated area.
3. Verify every responsible party. Match prescriber license, dispensing pharmacy, maker, prescription, lot, and contact information.
4. Put household exposure controls in writing. Require clear drying, washing, contact, linen, storage, spill, and disposal instructions.
5. Define monitoring and alternatives. Document baseline symptoms, response interval, adverse-effect route, refill ownership, and what would change the plan.

The decisive question is not “Is topical safer than oral?” It is “What exact dose and formula will reach this scalp and potentially the bloodstream, who compounded it under what conditions, and what monitoring and transfer controls are documented?”